Three-year follow-up data supports safety, efficacy of Boston Scientific's Taxus Express stent

By Lisa Kerner

Erie, Pa., May 16 - Three-year follow-up data from Boston Scientific Corp.'s Taxus VI clinical trial demonstrated that the safety and efficacy benefits associated with a moderate-release formulation of the Taxus Express paclitaxel-eluting stent system were maintained at three years.

In the randomized, double-blind, controlled study of 448 high-risk patients, lesion size ranged from 18 mm to 40 mm in length and 2.5 mm to 3.75 mm in diameter.

"The Taxus VI results show continuing patient benefits in the longest lesions ever studied in a randomized clinical trial," chief operating officer Paul LaViolette said in a news release.

"This data is consistent with the strong, long-term safety and efficacy results seen with the slow-release Taxus formulation and attests to the durability of the moderate-release technology even among this high-risk patient population."

Analysis of the data was presented by the co-principal investigator of the trial, Keith D. Dawkins, at the annual Paris Course on Revascularization.

Located in Natick, Mass., Boston Scientific develops, manufactures and markets medical devices for use in interventional medical specialties.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.